Login
$LGND
$306.75 -$2.04 (0.66%) Live

$LGND 8-K SEC Filings

Filed On Filing
29 Oct 2026 8-K: Results of Operations and Financial Condition

Third-quarter royalty revenue up 51% year-over-year to $70.3 million

24 Sep 2026 8-K: Regulation FD Disclosure; Other Events

Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million

22 Sep 2026 8-K: Regulation FD Disclosure

Ryjunea is the first and only pharmacologic treatment approved by the European Commission and UK MHRA to slow myopia progression in pediatric patients

06 Aug 2026 8-K: Results of Operations and Financial Condition

Second quarter performance driven by strong year-over-year royalty revenue growth of 32%

14 Jul 2026 8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +2 more

Acquisition adds seven commercial products including VABYSMO® (faricimab-svoa), OJEMDA™ (tovorafenib), and MIPLYFFA® (arimoclomol), and more than 100 development and commercial-stage assets, creating long-term opportunities to drive growth

25 Jun 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +2 more

INDENTURE dated as of June 25, 2026 between LIGAND PHARMACEUTICALS INCORPORATED, a Delaware corporation, as issuer (the “Company,” as more fully set forth in Section 1.01) and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, a national ban...

22 Jun 2026 8-K: Entry into a Material Definitive Agreement; Other Events

WARNING: The following actions may trigger Austrian stamp duty:

09 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

The 2026 Annual Meeting of the Stockholders of Ligand Pharmaceuticals Incorporated (the “Company”) was held on June 5, 2026 (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders approved an amendment and restatement o...

18 May 2026 8-K: Entry into a Material Definitive Agreement

This AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER (this “Amendment”) is made as of May 16, 2026, with respect to that certain Agreement and Plan of Merger, dated as of April 27, 2026 (the “Merger Agreement”), by and among Ligand Pharm...

07 May 2026 8-K: Results of Operations and Financial Condition

First quarter performance driven by strong year-over-year royalty revenue growth of 56%

30 Apr 2026 8-K: Termination of a Material Definitive Agreement

On April 24, 2026, Ligand Pharmaceuticals Incorporated (the “Company”) delivered written notice to Viking Therapeutics, Inc. (“Viking”) of termination of the TR-Beta Program (the “Termination Notice”) under that certain Master License Ag...

27 Apr 2026 8-K: Entry into a Material Definitive Agreement; Other Events

This AGREEMENT AND PLAN OF MERGER (as amended, restated, modified or supplemented, this “Agreement”), dated as of April 27, 2026, is by and among (i) Ligand Pharmaceuticals Incorporated, a Delaware corporation (“Parent”), (ii) Flex Merge...

26 Feb 2026 8-K: Results of Operations and Financial Condition

Robust financial performance driven by full year 2025 royalty revenue growth of 48%

18 Dec 2025 8-K: Regulation FD Disclosure

On December 18, 2025, Ligand Pharmaceuticals Incorporated (“Ligand”) posted materials regarding its private placement investment in Athira Pharma, Inc. on its investor relations page and certain of its social media accounts.

06 Nov 2025 8-K: Results of Operations and Financial Condition

Third quarter performance driven by strong portfolio royalty revenue growth of 47%

16 Sep 2025 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation

WARNING: The following actions may trigger Austrian stamp duty:

14 Aug 2025 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +2 more

INDENTURE dated as of August 14, 2025 between LIGAND PHARMACEUTICALS INCORPORATED, a Delaware corporation, as issuer (the “Company,” as more fully set forth in Section 1.01) and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, a national b...

11 Aug 2025 8-K: Entry into a Material Definitive Agreement; Other Events

WARNING: The following actions may trigger Austrian stamp duty:

07 Aug 2025 8-K: Results of Operations and Financial Condition

Second quarter performance driven by strong portfolio royalty revenue growth of 57%

02 Jul 2025 8-K: Regulation FD Disclosure

Pelthos plans to launch ZELSUVMI™ for the treatment of Molluscum contagiosum infections in July 2025

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support